Clinical trials
High Risk Non-muscle Invasive Bladder Cancer clinical trials
Below are recruiting high risk non-muscle invasive bladder cancer clinical trials, each written for real people, not researchers. We’re tracking 40 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06637423RecruitingPhase 1/Phase 2
Study of sacituzumab tirumotecan for low-grade bladder cancer
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
Bakersfield, CaliforniaAges 18 years+ - NCT06732531RecruitingPhase 1/Phase 2
Testing a new drug for high-risk bladder cancer that came back after BCG
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06833073RecruitingPhase 2
Study of an mRNA vaccine and BCG for bladder cancer
This trial tests an experimental mRNA vaccine (V940) combined with BCG therapy for people with high-risk non-muscle invasive bladder cancer that hasn't spread. It aims to see if the vaccine can help the immune system better fight the cancer.
Bakersfield, CaliforniaAges 18 years+ - NCT06972615RecruitingPhase 2
Bladder chemo plus pembrolizumab for BCG-treated cancer
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
CABAAges 18 years+ - NCT07130578Recruiting
Urine DNA test to guide second bladder cancer surgery
This trial is testing whether a urine test for tumor DNA/RNA can help guide the decision for a second surgery in people with high-risk, non-muscle-invasive bladder cancer. It aims to see if the urine test can predict who needs the second surgery, potentially avoiding unnecessary procedures.
TianjinAges 18 years+ - NCT07187063Recruiting
Using urine tests to reduce checkups for bladder cancer
This trial tests whether monitoring urine tumor DNA can safely reduce how often patients need invasive cystoscopy checkups after initial treatment for non-muscle invasive bladder cancer.
Burlington, MassachusettsAges 18 years+ - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Birmingham, AlabamaAges 18 years+ - NCT07322263RecruitingPhase 2
Gemcitabine and docetaxel for bladder cancer that returned after BCG
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Iowa City, IowaAges 18–99 - NCT03193515Recruiting
Blood test to monitor bladder cancer returning
This trial tests a new blood test that looks for signs bladder cancer may be coming back in people with a recent history of bladder cancer. It may help by making surveillance easier, but you must still follow a scheduled bladder-check plan.
Los Angeles, CaliforniaAges 18 years+ - NCT07474519RecruitingPhase 4
Studying position and dwell time for BCG bladder cancer treatment
This trial tests whether changing your position while receiving BCG treatment (a liquid medicine placed directly into the bladder) can help it work better. You will wear a fitness tracker for a few days to monitor activity.
Columbus, OhioAges 18 years+ - NCT06662071Recruiting
Personalized bladder cancer treatment using organoid drug testing
This trial tests if using a patient's own tumor cells grown in a lab (organoids) can help choose the best chemotherapy to put directly into the bladder. It is for people with non-muscle invasive bladder cancer who need their first round of this treatment.
Binzhou, ShandongAges 18–80 - NCT07204132Recruiting
Freezing and Immunotherapy for Bladder Cancer
This study tests a combination treatment for people with early-stage bladder cancer who want to avoid bladder removal. It uses a freezing technique (cryoablation) inside the bladder along with immunotherapy drugs to see if this can cure the cancer while keeping the bladder.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT04617756RecruitingPhase 2
Durvalumab plus chemo before surgery for high-risk upper urinary tract cancer
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
Paris, Paris Cx 20Ages 18 years+ - NCT05943379RecruitingPhase 2
RC48 antibody plus gemcitabine for high-risk bladder cancer
This Phase 2 study tests RC48, an antibody-based drug, combined with gemcitabine to treat high-risk, non-muscle invasive bladder cancer that has not responded well to BCG or cannot receive BCG. It may help shrink tumors and reduce the chance of the cancer coming back.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06407947RecruitingEarly Phase 1
CT071 for high-risk newly diagnosed multiple myeloma
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Kingman, ArizonaAges 18 years+
Hear when a new High Risk Non-muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk non-muscle invasive bladder cancer?
- Yes. Clin2 currently lists 40 recruiting high risk non-muscle invasive bladder cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk non-muscle invasive bladder cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk non-muscle invasive bladder cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Muscle Invasive Bladder Cancer
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Muscle Invasive Bladder Cancer (MIBC)
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Non-Muscle Invasive Bladder Neoplasms
- Non-Muscle Invasive Bladder Carcinoma
- Recurrent Non-Muscle Invasive Bladder Carcinoma
- Non Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.